Tiapride hydrochloride_51012-33-0_DataSheet_MedChemExpress

Product Name:Bendamustine hydrochloride

CAS No.: 3543-75-7

Cat. No.:HY-B0077Product Data Sheet

MWt:394.72

Formula:C16H22Cl3N3O2

Purity :>98%

Solubility:DMSO 79 mg/mL y

Mechanisms:

Biological Activity:

BendamustineHcl(SDX105;EP3101)isaDNAdamagingagentwithIC50of50M Pathways:Others; Target:Others

Water 15 mg/mL

Ethanol 17 mg/mL

Bendamustine Hcl(SDX105; EP-3101) is a DNA-damaging agent with IC50 of 50 μM.

Target: Others

Approved: March 2008

Treatment with Bendamustine results in a 60% to 80% down-regulation of the mRNA expression of

all three of these genes [polo-like kinase 1 (PLK-1), Aurora Kinase A, and cyclin B1] in SU-DHL-9

cells. Twenty-six percent of the Bendamustine-treated MCF-7/ADR cells showed micronucleation

compared with only 6% in DMSO control cells [1]. Using Bendamustine alone in concentrations from

Inhibitors, Agonists, Screening Libraries

Data Sheet

BIOLOGICAL ACTIVITY: 

Pyrantel tartrate is an antinematodal thiophene; nicotinic receptor agonist and can elicit spastic muscle paralysis in parasitic worms

due to prolonged activation of the excitatory nicotinic acetylcholine (nACh) receptors on body wall muscle.

References:

[1]. Aceves J, et al. The mechanism of the paralysing action of tetramisole on Ascaris somatic muscle. Br J Pharmacol. 1970 May;38(3):602–7.

[2]. Aubry ML, et al. Aspects of the pharmacology of a new anthelmintic: pyrantel. Br J Pharmacol. 1970 Feb;38(2):332–44.Product Name:Pyrantel (tartrate)

Cat. No.:HY-12641

CAS No.:33401-94-4

Molecular Formula:C

15H

20N

2O

6S

Molecular Weight:356.39

Target:Parasite

Pathway:Anti–infection

Solubility:

DMSO: ≥ 34 mg/mL

Caution: Product has not been fully validated for medical applications. For research use only.

Inhibitors, Agonists, Screening

Safety Data SheetRevision Date:Jul.-06-2017Print Date:Jul.-06-2017

1. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Sarpogrelate (hydrochloride)

Catalog No. :HY-10564

CAS No. :135159-51-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USA

Tel:609-228-6898

Fax:609-228-5909

E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-6898

2. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.

Inhibitors, Agonists, Screening Data Sheet

BIOLOGICAL ACTIVITY: Tolimidone is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM.IC50 & Target: EC50: 63 nM (Lyn kinase)[1]In Vitro: Incubation of Tolimidone (MLR–1023) with Lyn kinase elicits a repeatable 50% increase in enzyme activity. Tolimidone elicits aconcentration–dependent increase in Lyn kinase activation with a 2.3– and 2.1–fold increase achieved at concentrations of 3 and 10μM, respectively. Inclusion of Tolimidone (100 μM) increases Lyn kinase activity by 3–fold at each ATP concentration tested (Vmax=2601 U/mg). Tolimidone–mediated activation of Lyn kinase increases in proportion to the length of preincubation period in the absenceof ATP[1]. In Vivo: Administration of Tolimidone (MLR–1023) (30 mg/kg i.p.) significantly (p<0.05) lowers blood glucose levels to 148 and 158mg/dL, 30 and 90 min after administration, respectively. Tolimidone significantly increases adipocyte differentiation and adiponectinproduction by 3.7– and 19–fold, respectively[1]. Tolimidone elicits a dose–dependent potentiation of the insulin response, with amaximal effect observed with a dose level of 30 mg/kg[2]. PROTOCOL (Extracted from published papers and Only for reference) Kinase Assay:[1]For each kinase assay, Tolimidone (MLR–1023) (10 μM) is preincubated with kinase and fluoroscein–labeled proteinsubstrate. The reaction is initiated with the addition of ATP (at a concentration at or below the Km for each kinase), and the level offluoroscein phosphopeptide is measured. The assays are conducted in duplicate[1].Cell Assay: The concentration of Tolimidone is 10 μM for all assays.[1]Adipocyte differentiation is assessed in mouse 3T3–L1 cells after8 days of incubation with Tolimidone (MLR–1023) or rosiglitazone (10 μM). PPAR (α, σ and γ) transactivation studies are conducted intransiently transfected cells containing the appropriate DNA constructs (pGAL4/PPARα, σ or γ) cotransfected with a luciferase reportervector. Tolimidone or an appropriate reference compound is incubated with transfected cells for 24 h. Luciferase activity is monitoredas a measure of PPARα, σ and γ activation[1].Animal Administration: Tolimidone (MLR–1023) is formulated in 0.5% carboxymethyl cellulose and 0.025% Tween 80 inphosphate–buffered saline. [1]Male mice, 8 to 10 weeks of age, are used in studies of baseline glucose, glucose tolerance, and insulinlevels. Tolimidone (MLR–1023) is administered intraperitoneally at dose volumes of 5 to 10 mL/kg. Blood (5 μL) is acquired from a tailsnip and directly applied to a glucose test strip. Blood levels of Tolimidone are measured by liquid chromatography/tandem massspectrometry, and levels are determined by comparing them with a standard curve of Tolimidone prepared in blood[1].Product Name:TolimidoneCat. No.:HY-59047CAS No.:41964-07-2Molecular Formula:C11H10N2O2Molecular Weight:202.21Target:SrcPathway:Protein Tyrosine Kinase/RTKSolubility:DMSO